IFX-101 / Infinimmune - LARVOL DELTA

Preclinical development of IFX-101, an anti-IL-22 antibody, for the treatment of moderate-to-severe atopic dermatitis (EADV 2026) - "Together these data suggest that IFX-101 supports a potential human dosing interval of every 3 to 6 months. Conclusions We believe that the combination of a distinct mechanism of action relative to existing therapeutics and superior drug exposure and dosing schedule enabled by the long half life of IFX-101 will have a positive impact on AD patients, particularly those for whom existing therapies have failed."

Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • IL22 • IL23A • IL4

Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease (Businesswire) - "The financing will accelerate clinical development of Infinimmune’s two lead programs in atopic dermatitis, support advancement of additional programs leveraging human-first biology to address unmet clinical needs, and enable continued deployment of the company's Anthrobody discovery platform. Infinimmune will initiate first-in-human studies for its two lead programs in 2027. Infinimmune is advancing a pipeline of fully human antibodies...including: (i) IFX-101 - a first and best-in-class monoclonal antibody targeting IL-22; (ii) IFX-201 - a best-in-class monoclonal antibody targeting IL-13."

Financing • First-in-human • New trial • Atopic Dermatitis

Preclinical Development of an Anti-IL-22 Antibody for the Treatment of Atopic Dermatitis (FOCIS 2026) - "From these we have selected a lead candidate, IFX-101, which demonstrates high affinity ( < 10pM) and in vitro potency (IC50 ≤ 10pM), as well as strong in vivo potency evidenced by significant reduction in ear thickening even at low (0.1mg/kg) dosing. In addition to superior potency, IFX-101 is half-life extended to a projected human half-life of ~76 days, which enables a patient preferred quarterly dosing profile or better.We believe that the combination of a distinct mechanism of action relative to existing therapeutics and superior drug exposure and dosing schedule enabled by the long half life of this candidate will have a positive impact on AD patients, particularly those for whom existing therapies have failed."

Preclinical • Atopic Dermatitis • Dermatitis • Immunology • IL13 • IL22 • IL4

Preclinical development of IFX-101, an anti-IL-22 antibody, for the treatment of moderate-to-severe atopic dermatitis (SID 2026) - "These data suggest that IFX-101 supports a potential human dosing interval of every 3 to 6 months. We believe that the combination of a distinct mechanism of action relative to existing therapeutics and superior drug exposure and dosing schedule enabled by the long half life of IFX-101 will have a positive impact on AD patients, particularly those for whom existing therapies have failed."

Late-breaking abstract • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13 • IL22 • IL4